Ultrase MT20

Ultrase MT20 is a pancreatic enzyme replacement therapy (PERT) developed by Forest Laboratories for the treatment of exocrine pancreatic insufficiency (EPI), particularly in patients with cystic fibrosis. It contains pancrelipase, a porcine-derived mixture of digestive enzymes including lipase, amylase, and protease. The "MT" designation refers to the "minitablet" technology, which utilizes enteric-coated microspheres within a capsule to protect the enzymes from degradation by gastric acid. This formulation ensures that the enzymes are released in the alkaline environment of the duodenum, where they facilitate the hydrolysis of fats, proteins, and starches into absorbable nutrients. Historically, Ultrase was one of several pancreatic enzyme products marketed before the FDA mandated formal New Drug Applications (NDAs) for all such products in 2010; Forest Laboratories subsequently discontinued the product line rather than pursuing the new regulatory requirements.

Brand names

UltraseUltrase MT20Ultrase MT12Ultrase MT

Other names

pancrelipasepancreatic enzymespancreatin